Naltrexone-Bupropion Combination for Amphetamine Use Disorder
Naltrexone-bupropion combination is NOT approved for amphetamine/methamphetamine use disorder, but emerging evidence from the ADAPT-2 trial shows modest efficacy and represents the only pharmacotherapy with demonstrated benefit for this indication. While the FDA has only approved this combination for obesity management, off-label use for methamphetamine use disorder shows a treatment response of 13.6% versus 2.5% with placebo—a statistically significant but clinically modest effect 1.
Evidence Base and Efficacy
The most robust evidence comes from the 2021 ADAPT-2 trial, which used extended-release injectable naltrexone (380 mg every 3 weeks) plus oral extended-release bupropion (450 mg daily) in 403 adults with moderate-to-severe methamphetamine use disorder 1. The primary outcome—achieving at least 3 out of 4 methamphetamine-negative urine samples—occurred in only 16.5% of treated patients in stage 1 versus 3.4% with placebo. The overall weighted response across both trial stages was 13.6% with active treatment versus 2.5% with placebo, yielding an 11.1 percentage point treatment effect (P<0.001) 1.
Extended observation through 12 weeks showed continued benefit, with a 27.1% increase in probability of testing methamphetamine-negative among those receiving naltrexone-bupropion throughout both stages, compared to 11.4% with placebo—a 15.8% greater reduction (P=0.006) 2.
Mechanism of Action
The therapeutic effect appears mediated primarily through reduction in craving, which accounts for 56% of the treatment effect on self-reported use and 45% on drug screen-confirmed use 3, 4. Early reduction in depressive symptoms (by week 4) also predicts subsequent methamphetamine treatment response, explaining approximately 25% of the medication's effect 5.
Dosing Protocol
Standard dosing regimen (adapted from obesity treatment guidelines, as no specific MUD protocol exists):
- Naltrexone: Extended-release injectable 380 mg intramuscularly every 3 weeks 1
- Bupropion ER: Titrate from 150 mg daily to target dose of 450 mg daily 1
- Week 1: 150 mg once daily (morning)
- Week 2: 150 mg twice daily
- Week 3+: 300 mg morning + 150 mg afternoon, OR 450 mg once daily formulation
Dose adjustments:
- Moderate-to-severe renal impairment: Reduce bupropion to 150 mg twice daily 6
- End-stage renal disease: Avoid use 6
- Moderate-to-severe hepatic impairment: Maximum 150 mg bupropion daily 6
- Elderly patients (>65 years): Use caution due to increased CNS sensitivity 7
Critical Contraindications and Precautions
Absolute Contraindications
- Seizure disorders or conditions lowering seizure threshold 7, 6
- Concurrent or recent (within 14 days) MAOI use (risk of hypertensive crisis) 8
- Chronic opioid therapy (naltrexone blocks opioid effects and can precipitate withdrawal) 6
- Acute opioid withdrawal 6
- Uncontrolled hypertension 7, 6
- Pregnancy and breastfeeding 7
- Anorexia nervosa or bulimia 7
- Abrupt discontinuation of alcohol, benzodiazepines, or antiepileptics 7
Important Warnings
Bupropion exhibits amphetamine-like properties in preclinical studies and produced "mild amphetamine-like activity" in human abuse liability studies 9. However, at therapeutic doses in divided administration, it is unlikely to be reinforcing to stimulant abusers 9. Nonetheless, this pharmacologic similarity raises theoretical concerns about using it to treat amphetamine addiction.
Seizure risk: Dose-dependent; avoid doses exceeding 450 mg daily 7. Risk increases with:
- History of head trauma
- CNS tumor
- Eating disorders
- Concurrent medications lowering seizure threshold
Neuropsychiatric effects: Monitor for depression, suicidal ideation (especially in patients <24 years), mania, or psychosis 8, 6. While phase 3 obesity trials showed no increased depression rates (6.3% vs 5.9% placebo) 8, patients with severe psychiatric illness were excluded from these studies 8.
Monitoring Requirements
Baseline Assessment
- Comprehensive psychiatric evaluation (depression, suicidality, psychosis history)
- Seizure history and risk factors
- Current medications (especially opioids, MAOIs, other bupropion products)
- Blood pressure and heart rate
- Renal and hepatic function
- Pregnancy test in women of childbearing potential
- Baseline urine drug screen
Ongoing Monitoring
- Blood pressure and heart rate: At each visit, especially first 12 weeks (modest increases observed in trials) 6, 7, 6
- Neuropsychiatric symptoms: Every visit, particularly first 8 weeks
- Urine drug screens: Twice weekly to assess treatment response 1
- Craving assessment: Reduction in craving is the primary mediator of efficacy 3, 4
- Depressive symptoms: Early improvement (by week 4) predicts treatment response 5
Response Assessment
Discontinue if no response by 12 weeks on maintenance dose, defined as failure to achieve significant reduction in methamphetamine use 6. The ADAPT-2 trial used 3 out of 4 negative urine screens as the response criterion 1.
Clinical Considerations for Amphetamine Use Disorder
Realistic Expectations
The absolute response rate is low (13.6%), though significantly better than placebo 1. This represents the only pharmacotherapy with demonstrated efficacy for methamphetamine use disorder in rigorous trials, as no FDA-approved medications exist for this indication 10, 11.
Patient Selection
Machine learning analysis suggests certain baseline characteristics predict better response, though the classification rule requires validation 12. Consider prioritizing naltrexone-bupropion for patients with:
- Comorbid depression (bupropion has antidepressant effects) 6
- Concurrent smoking cessation needs 6
- High baseline craving (as craving reduction mediates efficacy) 3, 4
Integration with Behavioral Interventions
Contingency management (CM) remains the most effective intervention for methamphetamine use disorder, increasing abstinence rates by 40-60% 11. Naltrexone-bupropion should be combined with CM or other evidence-based behavioral therapies, not used as monotherapy.
Procedural Planning
Discontinue naltrexone-bupropion before procedures requiring opioid analgesia (e.g., endoscopy with fentanyl, surgery) to avoid blocking analgesic effects 6. Plan discontinuation at least 72 hours before anticipated opioid need.
Common Adverse Effects
From ADAPT-2 trial and obesity studies 6, 7, 6, 1:
- Gastrointestinal: Nausea (most common reason for discontinuation: 4.6-9.6%), vomiting, constipation
- Neurological: Headache, dizziness, tremor
- Psychiatric: Insomnia (avoid late-day dosing), anxiety
- Other: Hyperhidrosis, anorexia, dry mouth
Discontinuation rate due to adverse effects: 25% versus 10% with placebo 6.
Serious adverse events occurred in 3.6% of treated participants in ADAPT-2 1. No completed suicides were reported in obesity trials up to 56 weeks 8.
Critical Gap: Cardiovascular Safety
Long-term cardiovascular safety remains unclear 6. The FDA-mandated cardiovascular outcomes trial was terminated early after confidential data release, and a subsequent trial was stopped due to poor recruitment 6. Use caution in patients with cardiovascular disease, and monitor blood pressure and heart rate closely.